Skip to main content
. Author manuscript; available in PMC: 2020 Sep 24.
Published in final edited form as: Eur J Cancer. 2020 Apr 16;131:89–97. doi: 10.1016/j.ejca.2020.02.048

Figure 1:

Figure 1:

RSPO2 rs555008 and overall survival among patients with KRAS wild-type tumors. A Training cohort: RSPO2 rs555008 and OS (FIRE-3 FOLFIRI/bevacizumab arm). B Validation cohort: RSPO2 rs555008 and OS (TRIBE FOLFIRI/bevacizumab arm). C Control cohort: RSPO2 rs555008 and OS (FIRE-3 FOLFIRI/cetuximab arm).